Dexelvucitabine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dexelvucitabine
Dexelvucitabine.svg
Identifiers
CAS number 134379-77-4 YesY
PubChem 64973
ChemSpider 58498
KEGG D03981 YesY
ChEMBL CHEMBL109831
Jmol-3D images Image 1
Properties
Molecular formula C9H10FN3O3
Molar mass 227.19 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY (verify) (what is: YesY/N?)
Infobox references

Dexelvucitabine is a failed experimental agent for the treatment of HIV. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.

On April 3, 2006, Pharmasset and Incyte Corporation, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia in a phase II trial.